Form 4: Fractyl Health Director Receives Stock Option Grant

Director Kelly Ann Barnes was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Summary

• Kelly Ann Barnes, a director at Fractyl Health, Inc. (GUTS), was awarded 22,500 stock options.
• The options have an exercise price of $0.7318 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon potential future exercise of the options.

Risks

• Vesting is contingent upon continued service on the board of directors.
• Market volatility could impact the future value of the granted options.

Future Outlook

The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants for non-employee directors are standard corporate governance practice in the biotechnology sector to attract and retain board talent.

Comparison to Industry Standards

• The grant follows standard industry practices for non-employee director compensation in small-cap biotech firms.
• The vesting schedule is consistent with typical one-year cliff vesting structures for board members.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the grant relative to total outstanding shares.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Fractyl Health, GUTS, Form 4, Director Compensation, Stock Options, Insider Transaction